BACKGROUND: The marked improvement in outcome following induction of hypothermia after cardiac arrest has spurred the search for better methods to induce cooling. A regulated decrease in core temperature mediated by a drug-induced reduction in the set point for thermoregulation may be an ideal means of inducing hypothermia. To this end, the exploratory drug HBN-1 was assessed as a means to induce mild and prolonged hypothermia. METHODS: Free moving rats were infused i.v. for 12 hours with: a vehicle at room temperature (normothermia), a vehicle chilled to 4°C (forced hypothermia), or HBN-1 (mixture of ethanol, lidocaine, and vasopressin) at room temperature. Core (intra-abdominal) temperature (Tc) was measured telemetrically, tail skin temperature (Ttail) by infrared thermography, metabolic rate (MR) was estimated with indirect calorimetery, and shivering was scored visually. RESULTS: HBN-1 elicited a reduction in Tc from 37.5°C to 34°C within 80 minutes after initiation of the infusion; Tc was maintained between 33°C and 34°C for more than 13 hours. HBN-1 infusion was associated with a reduction in MR (p=0.0006), a slight reduction in Ttail, and no evidence of shivering (p<0.001). The forced hypothermia group displayed shivering (p<0.001), a significant increase in MR, and a decrease in Ttail, indicative of peripheral vasoconstriction to reduce heat loss. CONCLUSION: HBN-1 infusion induced a mild and prolonged hypothermia in free moving, unanesthetized rats characterized by modulation of thermoeffectors to reduce heat gain and increase heat loss. HBN-1 thus appears to elicit regulated hypothermia and may provide a new method for achieving a prolonged state of therapeutic hypothermia.
BACKGROUND: The marked improvement in outcome following induction of hypothermia after cardiac arrest has spurred the search for better methods to induce cooling. A regulated decrease in core temperature mediated by a drug-induced reduction in the set point for thermoregulation may be an ideal means of inducing hypothermia. To this end, the exploratory drug HBN-1 was assessed as a means to induce mild and prolonged hypothermia. METHODS: Free moving rats were infused i.v. for 12 hours with: a vehicle at room temperature (normothermia), a vehicle chilled to 4°C (forced hypothermia), or HBN-1 (mixture of ethanol, lidocaine, and vasopressin) at room temperature. Core (intra-abdominal) temperature (Tc) was measured telemetrically, tail skin temperature (Ttail) by infrared thermography, metabolic rate (MR) was estimated with indirect calorimetery, and shivering was scored visually. RESULTS: HBN-1 elicited a reduction in Tc from 37.5°C to 34°C within 80 minutes after initiation of the infusion; Tc was maintained between 33°C and 34°C for more than 13 hours. HBN-1 infusion was associated with a reduction in MR (p=0.0006), a slight reduction in Ttail, and no evidence of shivering (p<0.001). The forced hypothermia group displayed shivering (p<0.001), a significant increase in MR, and a decrease in Ttail, indicative of peripheral vasoconstriction to reduce heat loss. CONCLUSION: HBN-1 infusion induced a mild and prolonged hypothermia in free moving, unanesthetized rats characterized by modulation of thermoeffectors to reduce heat gain and increase heat loss. HBN-1 thus appears to elicit regulated hypothermia and may provide a new method for achieving a prolonged state of therapeutic hypothermia.
Authors: Benjamin S Abella; James W Rhee; Kuang-Ning Huang; Terry L Vanden Hoek; Lance B Becker Journal: Resuscitation Date: 2005-02 Impact factor: 5.262
Authors: J C Froehlich; R B Stewart; T K Li; A K Mosemiller; D E McCullough; M C Ho; J M Kisner Journal: Alcohol Clin Exp Res Date: 2001-03 Impact factor: 3.455
Authors: Laurence M Katz; Varidhi Nauriyal; Shruti Nagaraj; Alex Finch; Kevin Pearlstein; Adam Szymanowski; Charles Sproule; Preston B Rich; B D Guenther; Robert D Pearlstein Journal: Crit Care Med Date: 2008-06 Impact factor: 7.598
Authors: Neeraj Badjatia; Robert G Kowalski; J Michael Schmidt; Marc E Voorhees; Jan Claassen; Noeleen D Ostapkovich; Mary Presciutti; E Sander Connolly; David Palestrant; Augusto Parra; Stephan A Mayer Journal: Neurocrit Care Date: 2007 Impact factor: 3.210
Authors: Laurence M Katz; Jonathan E Frank; Lawrence T Glickman; Gerald McGwin; Brice H Lambert; Christopher J Gordon Journal: Resuscitation Date: 2015-04-20 Impact factor: 5.262
Authors: Isaac R Bailey; Bernard Laughlin; Lucille A Moore; Lori K Bogren; Zeinab Barati; Kelly L Drew Journal: J Pharmacol Exp Ther Date: 2017-06-26 Impact factor: 4.030
Authors: Rishabh C Choudhary; Muhammad Shoaib; Samantha Sohnen; Daniel M Rolston; Daniel Jafari; Santiago J Miyara; Kei Hayashida; Ernesto P Molmenti; Junhwan Kim; Lance B Becker Journal: Front Med (Lausanne) Date: 2021-05-18